HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Suppression of Active HIV-1 Infection in CD34+ Hematopoietic Humanized NSG Mice by a Combination of Combined Antiretroviral Therapy and CCR5 Targeting Drugs.

Abstract
Significant progress has been made in the diagnostics and treatment of AIDS since the discovery of the human immunodeficiency virus type 1 (HIV-1) in 1983. The remarkable effectiveness of combined antiretroviral therapy (cART) is evidenced by mortality reduction, control of peripheral blood viral load, and in a nearly normal quality of HIV patients' lives. Remaining obstacles in treatment and cure are drug toxicities and side effects, viral resistance, persistence of HIV-1 reservoirs on termination of cART treatment, the cost of lifelong antiretroviral therapy, and the stigma associated with taking antiretroviral drugs. As determined by plasma viral RNA and peripheral blood mononuclear cells (PBMC) proviral DNA, we show improved suppression of productive HIV infection in human CD34+ hematopoietic stem cell-engrafted NOD (nonobese diabetic)-SCID (severe combined immunodeficiency)-il2rg-/- (NSG) mice by combined treatment with cART and CCR5 targeting drugs, compared with cART alone, as well as an increased preservation of human CD4+ T cells (defined as CD45+ CD3+ CD4+ cells) and CD4+/CD8+ cell ratios in infected mice. The data also suggest a possible reduction in viral reservoirs. Our data confirm that this animal model is suitable for detection of productive HIV infection, replication, and establishment of viral reservoirs. The data also provide proof of principle for the utility of combining CCR5 targeting drugs, maraviroc and rapamycin, with traditional cART to improve control of viremia and reduce viral reservoirs. This study thus serves as a model for future HIV-1 studies that could lead to the clinical development of new generations of antiretroviral drugs.
AuthorsOlga S Latinovic, Lauren M Neal, Yutaka Tagaya, Alonso Heredia, Sandra Medina-Moreno, Juan C Zapata, Marvin Reitz, Joseph Bryant, Robert R Redfield
JournalAIDS research and human retroviruses (AIDS Res Hum Retroviruses) Vol. 35 Issue 8 Pg. 718-728 (08 2019) ISSN: 1931-8405 [Electronic] United States
PMID31099257 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-HIV Agents
  • Antigens, CD34
  • CCR5 protein, mouse
  • Il2rg protein, mouse
  • Interleukin Receptor Common gamma Subunit
  • Receptors, CCR5
  • Maraviroc
  • Sirolimus
Topics
  • Animals
  • Anti-HIV Agents (pharmacology)
  • Antigens, CD34 (metabolism)
  • CD4-CD8 Ratio
  • CD4-Positive T-Lymphocytes (immunology)
  • Disease Models, Animal
  • HIV Infections (drug therapy)
  • HIV-1 (drug effects)
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cells (virology)
  • Humans
  • Interleukin Receptor Common gamma Subunit (genetics)
  • Maraviroc (pharmacology)
  • Mice
  • Mice, Knockout
  • Mice, SCID
  • Receptors, CCR5 (drug effects)
  • Sirolimus (pharmacology)
  • Viral Load (drug effects)
  • Viremia (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: